Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Kun-Liang Guan
University of California, San Diego, Department: Pharmacology
Should you be removed from our database? Contact us at [email protected]. Read more below.
Vivace Therapeutics, Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Guan is a co-founder of Vivace Therapeutics, Inc. (Vivace) and holds (b)(4) equity in the company (valued between (b)(4)). The company focus is to develop inhibitors of YAP and TAZ to target cancer. Dr. Guan will help to oversee and supervise the studies of project Aim 2 regarding the analysis of how the YAP transcriptional coactivator is regulated by metformin in oral premalignant lesions and oral cancer initiation.
Targeting Signaling Vulnerabilities for Oral Cancer Prevention
Narrative There is an urgent need to develop prevention options to halt the progression of oral premalignant lesions (OPL) into oral squamous cell carcinoma (OSCC). Based on our laboratory findings and emerging epidemiological data, we have recently launched the NCI N01 Phase IIa Clinical Trial of metformin for oral cancer prevention trial (M4OC-Prevent, NCT02581137) to explore the potential use of metformin for OSCC prevention. By leveraging the wealth of clinical and genetic information and tissue and body fluid resources from this trial with our expertise in decoding cancer promoting pathways, the long-term goal of our project is to define mechanism-based biomarkers predicting a response to metformin and suitable therapeutic options to overcome drug resistance.
Filed on February 15, 2017.
Tell us what you know about Kun-Liang Guan's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Kun-Liang Guan”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Kun-Liang Guan | University of California, San Diego | Conflict of Interest | Vivace Therapeutics, Inc. | $0 - $4,999 |
| Kun-Liang Guan | University of California, San Diego | Conflict of Interest | Vivace Pharmaceuticals | $0 - $4,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.